NasdaqCM:MLTXBiotechs
MoonLake’s Sonelokimab Data Sharpens Risk Reward Profile Before Phase 3
MoonLake Immunotherapeutics reported positive topline Phase 2 results for Sonelokimab in axial spondyloarthritis.
The company plans to move Sonelokimab into Phase 3 trials, supported by recent regulatory feedback.
MoonLake is preparing for a future Biologics License Application and expanding development and manufacturing partnerships.
MoonLake Immunotherapeutics, listed as NasdaqCM:MLTX, is drawing fresh attention after the Sonelokimab Phase 2 readout in axial spondyloarthritis and plans...